Indication
Acyclovir-resistant mucocutaneous HSV in immunocompromised patient
Acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infection in an immunocompromised patient refers to a persistent, non-healing infection of the skin or mucous membranes caused by HSV-1 or HSV-2 that fails to respond to standard acyclovir therapy. Read more about Acyclovir-resistant mucocutaneous HSV in immunocompromised patient
13 drugs 12 manufacturers
Drugs that treat it
Common Acyclovir-resistant mucocutaneous HSV in immunocompromised patient therapies.
FOSCARNET SODIUM
FOSCARNET SODIUM
FOSCARNET SODIUM
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAcyclovir-resistant mucocutaneous herpes simplex virus (HSV) infection in an immunocompromised patient refers to a persistent, non-healing infection of the skin or mucous membranes caused by HSV-1 or HSV-2 that fails to respond to standard acyclovir therapy.
This condition primarily affects individuals with compromised cell-mediated immunity, such as hematopoietic stem cell or solid organ transplant recipients, individuals with advanced HIV infection, and patients undergoing immunosuppressive chemotherapy.
Pathophysiologically, it is most often driven by viral mutations in the thymidine kinase gene—and less frequently in the viral DNA polymerase gene—which prevent phosphorylation and bioactivation of acyclovir, valacyclovir, and often famciclovir.
Clinically, it manifests as chronic, painful, expanding, and often atypical ulcerative or verrucous mucocutaneous lesions—commonly involving the orofacial, anogenital, or perianal regions—that carry a heightened risk of secondary bacterial infection, severe tissue necrosis, and systemic dissemination.
- pharmacytimes.com
Acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infection in an immunocompromised patient refers to a persistent, non-healing infection of the skin or mucous membranes caused by HSV-1 or HSV-2 that fails to respond to standard acyclovir therapy Pathophysiologically, it is most often driven by viral mutations in the thymidine kinase gene—and less frequently in the viral DNA polymerase gene—which prevent phosphorylation and bioactivation of acyclovir, valacyclovir, and often famciclov...
- hiv.gov
Acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infection in an immunocompromised patient refers to a persistent, non-healing infection of the skin or mucous membranes caused by HSV-1 or HSV-2 that fails to respond to standard acyclovir therapy
- dermatologytimes.com
This condition primarily affects individuals with compromised cell-mediated immunity, such as hematopoietic stem cell or solid organ transplant recipients, individuals with advanced HIV infection, and patients undergoing immunosuppressive chemotherapy
- nih.gov
This condition primarily affects individuals with compromised cell-mediated immunity, such as hematopoietic stem cell or solid organ transplant recipients, individuals with advanced HIV infection, and patients undergoing immunosuppressive chemotherapy
- asm.org
Pathophysiologically, it is most often driven by viral mutations in the thymidine kinase gene—and less frequently in the viral DNA polymerase gene—which prevent phosphorylation and bioactivation of acyclovir, valacyclovir, and often famciclovir
- jhoponline.com
Clinically, it manifests as chronic, painful, expanding, and often atypical ulcerative or verrucous mucocutaneous lesions—commonly involving the orofacial, anogenital, or perianal regions—that carry a heightened risk of secondary bacterial infection, severe tissue necrosis, and systemic dissemination
- nih.gov
Clinically, it manifests as chronic, painful, expanding, and often atypical ulcerative or verrucous mucocutaneous lesions—commonly involving the orofacial, anogenital, or perianal regions—that carry a heightened risk of secondary bacterial infection, severe tissue necrosis, and systemic dissemination
Personalize your experience
Follow Acyclovir-resistant mucocutaneous HSV in immunocompromised patient and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.